The Business Research Company’s report on the Myasthenia Gravis Treatment Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the myasthenia gravis treatment market in recent years?
The surge in the prevalence of myasthenia gravis is expected to propel the growth of the myasthenia gravis treatment market going forward. Myasthenia gravis refers to an autoimmune neuromuscular disease condition in which patients experience fatigue and weakness in the skeletal muscles. Myasthenia gravis treatment is the process of providing health care IT & Communication Technology and taking care of a patient to combat myasthenia gravis. Thus, the surge in the prevalence of myasthenia gravis is boosting sales in the myasthenia gravis treatment market. For instance, in January 2022, according to the data published by the National Organization for Rare Disorders, a US-based non-profit organization providing support for individuals with rare diseases, autoimmune myasthenia gravis had an estimated prevalence of 14–40 per 100,000 individuals in the United States. For instance, in April 2024, according to the report published by the American Journal of Managed Care, a US-based peer-reviewed journal, based on an average of 1,800 diagnoses of myasthenia gravis (MG) annually, researchers estimated an annual incidence rate of 4.32 cases per 100,000 individuals and a rate of 2.46 cases per 100,000 person-years. Therefore, the surge in the prevalence of myasthenia gravis is driving the growth of the myasthenia gravis treatment market.
Access Your Free Sample of the Global Myasthenia Gravis Treatment Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp
What is the projected market size of the myasthenia gravis treatment industry, and how is it expected to grow?
The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.55 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, the emergence of plasma exchange, and patient advocacy
The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, and biosimilar medications. Major trends in the forecast period include digital therapeutics, collaborative research initiatives, patient-centric approaches, real-world evidence utilization, and long-term safety monitoring.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=11980&type=smp
Who are the key players driving competition in the myasthenia gravis treatment market?
Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics
What key trends are expected to drive the multiple myeloma drugs market during the forecast period?
Product innovations are a key trend gaining popularity in the myasthenia gravis treatment market. Major companies operating in the myasthenia gravis treatment market are focused on developing new solutions to sustain their position in the market. For instance, in October 2023, UCB Pharma, a Belgium-based pharmaceutical company, announced the US Food and Drug Administration (FDA) approved Zilucoplan. It is used for treating adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies. This approval introduces a new option in the management of gMG, which is characterized by muscle weakness due to an autoimmune response. ZILBRYSQ is notable for being a self-administered, once-daily subcutaneous complement C5 inhibitor. This provides a convenient alternative to traditional intravenous therapies that have been the standard for treating gMG.
Which key geographies are driving the growth of the myasthenia gravis treatment market?
North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report
What are the key segments driving growth in the myasthenia gravis treatment market?
The myasthenia gravis treatment market covered in this report is segmented –
1) By Treatment: Medication, Surgery, Other Treatments
2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types
3) By End-Use: Hospitals, Clinics, Other End-Uses
Subsegments:
1) By Medication: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Corticosteroids
2) By Surgery: Thymectomy
3) By Other Treatments: Plasmapheresis, Intravenous Immunoglobulin (IVIg), Supportive Therapies
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11980
What defines the structure and scope of the myasthenia gravis treatment market?
Myasthenia gravis treatment refers to the process of providing health care IT & Communication Technology by health care providers and taking care of a patient to combat myasthenia gravis, an autoimmune neuromuscular disease causing fatigue and weakness in the skeletal muscles.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
